ESPR Q3 2017 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$45M

EPS (Diluted)

$-1.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$313M

Total Liabilities

$35M

Stockholders' Equity

$278M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$46M	-$18M	-158.2%
Net Income	-$45M	-$17M	-159.8%